- New clinical trial (N=676) has shown that ketamine nasal spray treatment in patients with treatment-resistant depression led to higher rates (27.1%) of remission, after 8 weeks, than standard intervention with the antipsychotic drug quetiapine (17.6%) https://www.jnj.com/large-head-to-head-study-shows-patients-with-treatment-resistant-depression-receiving-spravato-esketamine-ciii-nasal-spray-were-1-54-times-as-likely-to-reach-remission-at-8-weeks-than-patients-treated-with-quetiapine-xr 73 comments science
- Johnson & Johnson Confirms Intent Not to Enforce Patents for SIRTURO® (bedaquiline) for the Treatment of Multidrug-Resistant Tuberculosis in 134 Low- and Middle-Income Countries https://www.jnj.com/johnson-johnson-confirms-intent-not-to-enforce-patents-for-sirturo-bedaquiline-for-the-treatment-of-multidrug-resistant-tuberculosis-in-134-low-and-middle-income-countries 38 comments worldnews
- What happens to Abiomed Stock now that J&J acquired it? https://www.jnj.com/johnson-johnson-to-acquire-abiomed 6 comments investing
- Johnson & Johnson Statement on COVID-19 Vaccine - We have made the decision to proactively delay the rollout of our vaccine in Europe https://www.jnj.com/johnson-johnson-statement-on-covid-19-vaccine 8 comments worldnews
- What do you think about Johnson & Johnson https://www.jnj.com/johnson-johnson-announces-single-shot-janssen-covid-19-vaccine-candidate-met-primary-endpoints-in-interim-analysis-of-its-phase-3-ensemble-trial 12 comments stocks
- Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial https://www.jnj.com/johnson-johnson-announces-single-shot-janssen-covid-19-vaccine-candidate-met-primary-endpoints-in-interim-analysis-of-its-phase-3-ensemble-trial 8 comments science
- Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial https://www.jnj.com/johnson-johnson-announces-single-shot-janssen-covid-19-vaccine-candidate-met-primary-endpoints-in-interim-analysis-of-its-phase-3-ensemble-trial 3 comments europe
- Johnson & Johnson and coronavirus vaccine https://www.jnj.com/johnson-johnson-announces-a-lead-vaccine-candidate-for-covid-19-landmark-new-partnership-with-u-s-department-of-health-human-services-and-commitment-to-supply-one-billion-vaccines-worldwide-for-emergency-pandemic-use 35 comments stocks
- Johnson & Johnson To Collaborate With Google To Advance Surgical Robotics http://www.jnj.com/news/all/johnson-johnson-announces-definitive-agreement-to-collaborate-with-google-to-advance-surgical-robotics 8 comments technology
- WTF Johnson & Johnson, what the hell did the internet ever do to you? This stops now.. details inside. http://www.jnj.com/connect/healthcare-products/consumer/ 48 comments politics